JP2007511203A - キナーゼ阻害活性を有するジアリール尿素 - Google Patents

キナーゼ阻害活性を有するジアリール尿素 Download PDF

Info

Publication number
JP2007511203A
JP2007511203A JP2006533211A JP2006533211A JP2007511203A JP 2007511203 A JP2007511203 A JP 2007511203A JP 2006533211 A JP2006533211 A JP 2006533211A JP 2006533211 A JP2006533211 A JP 2006533211A JP 2007511203 A JP2007511203 A JP 2007511203A
Authority
JP
Japan
Prior art keywords
acid
compound
formula
group
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511203A5 (enExample
Inventor
ウイルヘルム，スコット
デュマ，ジャック
ラドゥーソア，ガエタン
リンチ，マーク
スコット，ウイリアム、ジェイ
Original Assignee
バイエル、ファーマシューテイカルズ、コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33545309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007511203(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by バイエル、ファーマシューテイカルズ、コーポレイション filed Critical バイエル、ファーマシューテイカルズ、コーポレイション
Publication of JP2007511203A publication Critical patent/JP2007511203A/ja
Publication of JP2007511203A5 publication Critical patent/JP2007511203A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
JP2006533211A 2003-05-20 2004-05-19 キナーゼ阻害活性を有するジアリール尿素 Pending JP2007511203A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47173503P 2003-05-20 2003-05-20
US52039903P 2003-11-17 2003-11-17
US55606204P 2004-03-25 2004-03-25
PCT/US2004/015655 WO2004113274A2 (en) 2003-05-20 2004-05-19 Diaryl ureas with kinase inhibiting activity

Publications (2)

Publication Number Publication Date
JP2007511203A true JP2007511203A (ja) 2007-05-10
JP2007511203A5 JP2007511203A5 (enExample) 2007-06-21

Family

ID=33545309

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006533211A Pending JP2007511203A (ja) 2003-05-20 2004-05-19 キナーゼ阻害活性を有するジアリール尿素
JP2006533210A Expired - Lifetime JP4860474B2 (ja) 2003-05-20 2004-05-19 Ｐｄｇｆｒによって仲介される病気のためのジアリール尿素

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006533210A Expired - Lifetime JP4860474B2 (ja) 2003-05-20 2004-05-19 Ｐｄｇｆｒによって仲介される病気のためのジアリール尿素

Country Status (12)

Country Link
US (2) US8796250B2 (enExample)
EP (2) EP1636585B2 (enExample)
JP (2) JP2007511203A (enExample)
AT (2) ATE384264T1 (enExample)
CA (2) CA2526617C (enExample)
DE (2) DE602004011340T2 (enExample)
DK (2) DK1626714T3 (enExample)
ES (2) ES2288694T3 (enExample)
MX (1) MXPA05012486A (enExample)
PL (2) PL1626714T3 (enExample)
PT (2) PT1626714E (enExample)
WO (2) WO2005000284A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515400A (ja) * 2003-11-28 2007-06-14 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体
JP2009519265A (ja) * 2005-12-15 2009-05-14 バイエル・ヘルスケア・アクチェンゲゼルシャフト ウイルス感染を処置するためのジアリールウレア
JP2010516693A (ja) * 2007-01-19 2010-05-20 バイエル・ヘルスケア・エルエルシー Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置
JP2013238609A (ja) * 2007-05-18 2013-11-28 Inst Curie 膀胱癌における治療標的としてのｐ３８α
JP2016104785A (ja) * 2009-09-03 2016-06-09 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ チロシンキナーゼ調節剤としての化合物
JP2019528279A (ja) * 2016-08-17 2019-10-10 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害物質化合物、組成物、及びがんの治療方法
JP2020517600A (ja) * 2017-04-20 2020-06-18 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｋ−Ｒａｓモジュレーター

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
ES2400070T3 (es) * 2001-12-03 2013-04-05 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
MXPA04007832A (es) * 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
EP1615878B1 (en) * 2003-01-14 2012-04-04 Cytokinetics, Inc. Compounds, compositions and methods of treatment for heart failure
NZ577553A (en) * 2003-02-21 2011-01-28 Resmed Ltd Nasal assembly
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
HRP20060073B1 (hr) 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
US7803178B2 (en) * 2004-01-30 2010-09-28 Trivascular, Inc. Inflatable porous implants and methods for drug delivery
WO2006009726A2 (en) 2004-06-17 2006-01-26 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
PL1797038T3 (pl) * 2004-09-29 2012-11-30 Bayer Healthcare Llc Termodynamicznie trwała postać tosylanu bay 43-9006
BRPI0515944B1 (pt) 2004-09-29 2021-11-09 Bayer Healthcare Llc Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida
CN104688697A (zh) * 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
ATE493652T1 (de) * 2005-08-11 2011-01-15 Siemens Healthcare Diagnostics Quantitative assays für pdgfr-beta- in körperflüssigkeiten
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
EP1968589A2 (en) * 2005-10-31 2008-09-17 Bayer Pharmaceuticals Corporation Combinations comprising sorafenib and interferon for the treatment of cancer
EP1954272A2 (en) * 2005-10-31 2008-08-13 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
CA2628849A1 (en) * 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating pulmonary hypertension
WO2007054302A1 (en) * 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl ureas for treating diabetic neuropathy
JP5075832B2 (ja) * 2005-11-10 2012-11-21 バイエル・ファルマ・アクチェンゲゼルシャフト 肺高血圧を処置するためのジアリールウレア
MX2008006979A (es) * 2005-12-01 2009-01-14 Bayer Healthcare Llc Compuestos de urea utiles en el tratamiento contra el cancer.
TW200808321A (en) * 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US20070197505A1 (en) * 2005-12-15 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
EP1962829A1 (en) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryl ureas for treating virus infections
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP1962852B1 (en) * 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
EP1973897B1 (en) * 2005-12-21 2014-05-21 Bayer Intellectual Property GmbH Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
WO2008044688A1 (en) * 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Urea derivative
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2010522163A (ja) * 2007-03-20 2010-07-01 キュリス，インコーポレイテッド 亜鉛結合部位を含むＲａｆキナーゼインヒビター
US7674406B2 (en) * 2007-06-14 2010-03-09 Bindra Perminder S Chemiluminescent compositions and methods of making and using thereof
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物
MX2010014441A (es) * 2008-06-25 2011-01-21 Bayer Schering Pharma Ag Diaril ureas para tratar la insuficiencia cardiaca.
EP2296641A1 (en) * 2008-06-25 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
CN105574346A (zh) * 2008-09-05 2016-05-11 新基阿维罗米克斯研究公司 多肽偶联物与不可逆抑制剂的设计方法和检测方法
CN103254126A (zh) * 2008-09-19 2013-08-21 苏州泽璟生物制药有限公司 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
CN101362717B (zh) * 2008-09-28 2013-02-06 四川大学 4-(4-氨基苯胺基)-2-(甲基氨甲酰基)吡啶及其衍生物和它们的制备方法、用途
FR2943670B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives anticancereux,leur preparation et leur application en therapeutique
US7964119B2 (en) * 2009-05-12 2011-06-21 Mega Glow, LLC. Chemiluminescent powders and methods of making and using thereof
US8658066B2 (en) 2009-05-12 2014-02-25 Mega Glow, Llc Chemiluminescent powders and methods of making and using thereof
CN102459180B (zh) * 2009-06-09 2014-05-14 江苏迈度药物研发有限公司 作为激酶抑制剂的脲衍生物
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
CN102574781B (zh) 2009-09-30 2014-02-19 东丽株式会社 2，3-二氢-1h-茚-2-基脲衍生物及其药物用途
CN102812167A (zh) 2009-12-30 2012-12-05 阿维拉制药公司 蛋白的配体-介导的共价修饰
PL2528899T3 (pl) 2010-01-29 2015-02-27 Ranbaxy Laboratories Ltd Solwat sorafenibu z dimetylosulfotlenkiem
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN101830847B (zh) * 2010-05-18 2012-10-10 张南 抗癌用化合物及制备方法
WO2012012404A1 (en) * 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
AU2011310532B2 (en) * 2010-10-01 2016-01-14 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
WO2013000909A1 (en) 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing sorafenib
SG11201407216YA (en) * 2012-05-18 2014-12-30 Sanofi Sa Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists
WO2014040242A1 (zh) * 2012-09-12 2014-03-20 湖南有色凯铂生物药业有限公司 3-氯-及3-甲氧基-n-甲基-2-吡啶酰胺化合物及其作为抗癌药物的应用
EP2976081B1 (en) * 2013-03-15 2020-06-17 Alumend, LLC Methods of acute restoration of vascular compliance
RU2018134336A (ru) 2016-03-02 2020-04-02 Медивир Актиеболаг Комбинированная терапия сорафенибом или регорафенибом и фосфорамидатным пролекарством троксацитабина
CN108314703B (zh) * 2017-01-17 2022-02-01 亚飞（上海）生物医药科技有限公司 分子定点靶向和激活的激酶抑制剂的制备和用途
CN109771407B (zh) * 2019-03-29 2021-11-26 成都医学院 迷迭香酸在制备抑制水痘-带状疱疹病毒的药物中的用途
CN110054584B (zh) * 2019-05-28 2022-03-11 沈阳药科大学 1-芳基-3-{4-[(吡啶-2-基甲基)硫基]苯基}脲类化合物及应用
IT202000022636A1 (it) 2020-09-25 2022-03-25 Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma”
CN117143014A (zh) * 2023-08-02 2023-12-01 深圳海王医药科技研究院有限公司 一种乐伐替尼衍生物及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041698A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
WO2002085859A1 (en) * 2001-04-20 2002-10-31 Bayer Corporation HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
WO2002085857A2 (en) * 2001-04-20 2002-10-31 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas

Family Cites Families (505)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US502504A (en) 1893-08-01 Hermann thoms
US1792156A (en) 1928-01-17 1931-02-10 Gen Aniline Works Inc 5-halogen-2-amino-1-alkyloxy and 1-aralkyloxy-benzenes and intermediate products thereof and process of preparing them
US2093265A (en) 1931-03-31 1937-09-14 Ici Ltd Process for the manufacture of diaryl ureas
US2046375A (en) 1931-06-04 1936-07-07 Ici Ltd p-halogen-omicron-alkoxy-aniline derivatives and process of preparing the same
US2288422A (en) * 1938-11-11 1942-06-30 Gen Aniline & Film Corp Mixed ureas
US2973386A (en) * 1943-01-05 1961-02-28 Harry A Weldon Purification of sym dichloro-bis (2, 4, 6-trichlorophenyl)urea
DE925476C (de) 1950-04-29 1955-03-21 Variapat Ag Verfahren zur Herstellung von farblosen, wasserloeslichen, trifluormethyl- und sulfonsaeuregruppenhaltigen, aliphatischen oder aromatischen Carbonsaeure- bzw. Sulfonsaeurearyliden
US2683082A (en) 1950-12-09 1954-07-06 Ethyl Corp Nu-aryl-nu'-(p-hydroxyphenyl) ureas as antioxidants for petroleum hydrocarbon fuels
US2722544A (en) 1950-12-26 1955-11-01 Variapat Ag Trifluoromethyl halogenated diphenylcarbamide sulfonic acids and their preparation
US2781330A (en) 1953-02-09 1957-02-12 Monsanto Chemicals Rubber containing urea compound as an anti-exposure cracking agent
NL90162C (enExample) * 1953-03-06
US2745874A (en) 1953-06-18 1956-05-15 Geigy Ag J R Insecticidal derivatives of diphenyl urea
GB771333A (en) 1953-12-22 1957-03-27 Geigy Ag J R Improvements relating to halogen substituted diphenyl urea and thiourea compounds and their use
NL193403A (enExample) 1953-12-22 1924-02-17
GB828231A (en) 1955-10-20 1960-02-17 Geigy Ag J R Improvements relating to insecticidal compounds and their use
US2877268A (en) 1956-12-24 1959-03-10 Monsanto Chemicals Substituted ureas
US2960488A (en) * 1958-04-25 1960-11-15 Eastman Kodak Co Poly-alpha-olefins containing substituted ureas
NL254871A (enExample) * 1959-08-14
BE616734A (enExample) 1961-04-21
CH479557A (de) 1961-09-11 1969-10-15 Wander Ag Dr A Verfahren zur Herstellung neuer mehrbasischer Verbindungen
US3200035A (en) 1962-06-01 1965-08-10 Ciba Ltd Treatment of synthetic products, especially synthetic fibers
US3284433A (en) * 1963-07-17 1966-11-08 Merck & Co Inc 4-phenoxy-carbanilides
FR1457172A (fr) 1964-12-12 1966-10-28 Ferrania Spa Procédé pour la production d'images photographiques en couleurs et matériel photographique correspondant
FR90420E (enExample) 1965-06-09 1968-02-21
US3424761A (en) 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424760A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424762A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H Certain 3-ureidopyrrolidines
US3547940A (en) 1967-10-31 1970-12-15 Du Pont Substituted ureido isoxazoles
US3743498A (en) 1967-10-31 1973-07-03 Du Pont Method of selectively controlling undesirable vegetation
SE370866B (enExample) * 1968-03-21 1974-11-04 Ciba Geigy Ag
DE1768244A1 (de) * 1968-04-19 1971-10-14 Bayer Ag N-(2,2,4,4-Tetrafluor-1,3-benz-dioxanyl)-harnstoffe und Verfahren zu ihrer Herstellung
US3646059A (en) * 1969-05-05 1972-02-29 Du Pont Plant growth regulatory ureidopyrazoles
US3754887A (en) * 1969-05-05 1973-08-28 Du Pont Ureidopyrazoles defoliants
US3668222A (en) * 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin
BE754782A (fr) * 1969-08-14 1971-02-12 May & Baker Ltd Derives du thiophene a action herbicide
US3823161A (en) 1970-05-07 1974-07-09 Exxon Research Engineering Co Aminothiophene derivatives
US3860645A (en) 1973-05-23 1975-01-14 Givaudan Corp Bacteriostatic substituted carbanilides
US4111680A (en) * 1973-07-27 1978-09-05 Shionogi & Co., Ltd. Herbicidal compositions containing 3-isoxazolylurea derivatives
US4062861A (en) 1973-07-27 1977-12-13 Shionogi & Co., Ltd. 3-Isoxazolylurea derivatives
JPS5031039A (enExample) 1973-07-27 1975-03-27
US4212981A (en) 1973-07-27 1980-07-15 Shionogi & Co., Ltd. Process for preparing 3-isoxazolylurea derivatives
US4001256A (en) * 1973-12-26 1977-01-04 The Upjohn Company Pyridylalkyl phenyl ureas and their n-oxides
US3931201A (en) 1974-01-22 1976-01-06 The Dow Chemical Company Substituted pyridinyloxy(thio)phenyl -acetamides, -ureas and urea derivatives
US4009847A (en) 1974-04-17 1977-03-01 E. I. Du Pont De Nemours And Company 1-Tertiary-alkyl-3-(substituted thienyl)ureas and 1-tertiary-alkyl-3-(substituted thietyl)ureas as antihypertensive agents
US3990879A (en) * 1974-12-26 1976-11-09 Eli Lilly And Company Method of controlling aquatic weeds
US4111683A (en) 1975-06-27 1978-09-05 Chevron Research Company N-alkyl or alkoxy-N'-substituted hydrocarbyl urea
DE2637947C2 (de) 1976-08-24 1985-09-19 Bayer Ag, 5090 Leverkusen Tetrafluor-1,3-benzodioxanyl-benzoylharnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung als Insektizide
JPS5840946B2 (ja) * 1976-10-29 1983-09-08 石原産業株式会社 Ｎ−ベンゾイル−ｎ′−ピリジルオキシフエニルウレア系化合物、それらの製造方法及びそれらを含有する殺虫剤
US4173637A (en) * 1976-10-29 1979-11-06 Ishihara Sangyo Kaisha Ltd. N-Benzoyl-N'-pyridyloxy phenyl urea and insecticidal compositions thereof
US4071524A (en) 1976-11-08 1978-01-31 Riker Laboratories, Inc. Derivatives of urea
US4183854A (en) * 1976-11-10 1980-01-15 John Wyeth & Brother Limited Thiazole compound
US4042372A (en) * 1976-11-19 1977-08-16 Eli Lilly And Company Substituted thiadiazolotriazinediones and method of preparation
DE2817449A1 (de) 1978-04-21 1979-10-31 Bayer Ag Mittel zur regulierung des pflanzenwachstums
GB1590870A (en) 1978-05-31 1981-06-10 Shionogi & Co N-(5-t-butyl-3-isoxazolyl) alkanamide derivatives having herbicidal activity
JPS5562066A (en) 1978-11-03 1980-05-10 Toshihiko Okamoto N-(2-substituted-4-pyridyl)-urea and thio urea, their preparation and plant growth regulator
DE2848330A1 (de) * 1978-11-03 1980-05-14 Schering Ag Verfahren zur herstellung von 1,2, 3-thiadiazol-5-yl-harnstoffen
FI800559A7 (fi) 1979-03-14 1981-01-01 F Hoffmann La Roche & Co Virtsa-ainejohdannaiset.
JPS55124763A (en) * 1979-03-19 1980-09-26 Ishihara Sangyo Kaisha Ltd 5-trifluoromethyl-2-pyridone derivative
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4468380A (en) 1979-12-26 1984-08-28 Eli Lilly And Company Anticoccidial combinations comprising polyether antibiotics and carbanilides
WO1981002156A1 (en) 1980-01-25 1981-08-06 Reanal Finomvegyszergyar Process for the preparation of n-aryl-n'-(mono-or disubstiuted)-urea derivatives
DE3174885D1 (en) 1981-02-03 1986-07-31 Ici Plc Process for the extraction of metal values and novel metal extractants
US4526997A (en) 1981-05-06 1985-07-02 Doherty George O P O Anticoccidial combinations comprising polyether antibiotics and carbanilides
US4511571A (en) * 1981-10-20 1985-04-16 Ciba Geigy Corporation N-(2-Pyridyloxyphenyl)-N'-benzoyl ureas, pesticidal compositions containing same and pesticidal methods of use
US4623662A (en) 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
US4473579A (en) 1982-01-26 1984-09-25 American Cyanamid Company Antiatherosclerotic tetrasubstituted ureas and thioureas
DE3211851A1 (de) 1982-03-31 1983-10-06 Basf Ag Dihydrothiophen-carbonester, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
JPS58203957A (ja) * 1982-05-25 1983-11-28 Ube Ind Ltd 尿素誘導体の製法
AU1862083A (en) 1982-09-02 1984-03-08 Duphar International Research B.V. Tumor growth inhibitors
CA1254212A (en) * 1982-11-12 1989-05-16 Shiro Hirai Amine derivatives, salts thereof, process for preparing the same and an anti-ulcer agent containing the same
DE3305866A1 (de) 1983-02-19 1984-08-23 Basf Ag, 6700 Ludwigshafen Thiophen-carbonester, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
US4499097A (en) 1983-03-10 1985-02-12 American Cyanamid Company 2-(Pyridyl)imidazolyl ketones
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
US4540566A (en) 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
JPS6193163A (ja) * 1984-10-12 1986-05-12 Ishihara Sangyo Kaisha Ltd Ｎ−ベンゾイル−ｎ′−フエニルウレア系化合物、それらの製造方法並びにそれらを含有する抗癌剤
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
DE3529247A1 (de) 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
DE3540377A1 (de) 1985-11-14 1987-05-21 Bayer Ag Thienooxazinone, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer
DE3541631A1 (de) 1985-11-26 1987-05-27 Bayer Ag Selektiv-fungizide verwendung von thienylharnstoff-derivaten
AU594098B2 (en) 1985-12-11 1990-03-01 Ishihara Sangyo Kaisha Ltd. N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation
EP0230400A3 (de) 1986-01-21 1990-02-14 Ciba-Geigy Ag N-3-(5-Trifluormethyl-pyridyl-2-oxy)-phenyl-N'-benzoylharnstoffe zur Bekämpfung von Helminthen an Nutztieren
JPS62185013A (ja) 1986-02-08 1987-08-13 Green Cross Corp:The 易吸収性医薬組成物
DE3612830A1 (de) 1986-04-16 1987-10-22 Basf Ag Thiadiazolylharnstoff enthaltendes mittel zur entblaetterung von pflanzen
DE3785507T2 (de) 1986-07-31 1993-07-29 Beecham Group Plc Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
NZ221964A (en) 1986-10-03 1990-03-27 Ishihara Sangyo Kaisha Benzoylurea compounds and insecticidal compositions
US4983605A (en) 1986-10-23 1991-01-08 Ishihara Sangyo Kaisha Ltd. Pharmaceutical composition
DE3636190A1 (de) 1986-10-24 1988-04-28 Bayer Ag Verfahren zur herstellung von n,n-diaryl-harnstoffen
JPH06100808B2 (ja) 1987-05-28 1994-12-12 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料の処理方法
ES2070861T3 (es) 1987-10-16 1995-06-16 Ciba Geigy Ag Compuestos antiparasitarios.
DE3810382A1 (de) 1988-03-26 1989-10-12 Bayer Ag 5-amino-1-phenylpyrazole, verfahren sowie 5-halogen-1-phenylpyrazole als zwischenprodukte zu deren herstellung und ihre verwendung als herbizide
FI902021A7 (fi) 1988-08-23 1990-04-23 The Nutrasweet Company Substituoituja aryyliureoita suuritehoisina makeuttajina
JPH0278699A (ja) 1988-09-12 1990-03-19 Green Cross Corp:The ベンゾイルウレア系化合物・アルブミン複合体
FR2662692B1 (fr) 1990-05-30 1995-04-28 Novapharme Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique.
FR2639636B1 (fr) 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
JPH02196719A (ja) 1989-01-24 1990-08-03 Green Cross Corp:The 粉末状医薬組成物
JPH02237922A (ja) 1989-01-24 1990-09-20 Green Cross Corp:The 抗ウィルス剤
EP0379915A1 (de) 1989-01-26 1990-08-01 Bayer Ag Substituierte Phenoxybenzonitril-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und Pflanzenwuchsregulatoren
JP3002204B2 (ja) 1989-03-13 2000-01-24 株式会社東芝 時系列信号認識装置
US4973675A (en) 1989-04-13 1990-11-27 University Of Tennessee Research Center Hybrid nitrosoureidoanthracyclines having antitumor activity
JPH0395153A (ja) 1989-06-15 1991-04-19 Mitsubishi Kasei Corp ジフェニル尿素誘導体
US5665543A (en) 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
IL95860A0 (en) 1989-10-13 1991-07-18 Ciba Geigy Ag Thienylthioureas,-isothioureas and-carbodiimides
EP0425443A1 (de) 1989-10-27 1991-05-02 Ciba-Geigy Ag Injizierbares parasitizides Mittel
US5177110A (en) 1989-10-27 1993-01-05 Ciba-Geigy Corporation Injectable parasiticidal composition
WO1991019697A1 (fr) 1990-06-19 1991-12-26 Meiji Seika Kabushiki Kaisha Derive de pyridine avec antagonisme de l'angiotensine ii
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
GB9017892D0 (en) 1990-08-15 1990-09-26 May & Baker Ltd New compositions of matter
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
ATE157355T1 (de) 1991-01-21 1997-09-15 Shionogi & Co 3-benzyliden-1-carbamoyl-2-pyrrolidon-analoga
JP2671693B2 (ja) 1991-03-04 1997-10-29 松下電器産業株式会社 バイオセンサおよびその製造法
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5270458A (en) 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5185438A (en) 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
NO921449L (no) 1991-04-17 1992-10-19 American Home Prod Karbamater av rapamycin
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5185358A (en) 1991-06-24 1993-02-09 Warner-Lambert Co. 3-heteroatom containing urea and thiourea ACAT inhibitors
US5162360A (en) 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
WO1993004170A1 (en) 1991-08-23 1993-03-04 The United States Of America Represented By The Secretary, Department Of Health And Human Services Raf protein kinase therapeutics
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5565322A (en) 1991-11-07 1996-10-15 Nanogen, Inc. Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to donor energy transfer system
FR2683818B1 (fr) 1991-11-14 1993-12-31 Adir Cie Nouveaux derives de 3-sulfonylamino-2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5348853A (en) 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
JPH07504429A (ja) 1992-03-12 1995-05-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ＨＴ↓１ｃアンタゴニストとしてのインドール誘導体
DE4212407A1 (de) 1992-04-13 1993-10-14 Knorr Bremse Gmbh Lüftspieldetektor für eine druckluftbetätigte Scheibenbremse
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
CA2140653A1 (en) 1992-08-12 1994-03-03 Irene Abraham Protein kinase inhibitors and related compounds combined with taxol
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
JP2717481B2 (ja) 1992-08-25 1998-02-18 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
EP0672187A4 (en) 1992-10-08 1999-11-17 Univ California PCR TEST METHOD FOR DETERMINING PRESENCE AND CONCENTRATING A TARGET SUBSTANCE.
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
WO1994014801A1 (en) 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
US5512473A (en) 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
GB9302275D0 (en) 1993-02-05 1993-03-24 Smithkline Beecham Plc Novel compounds
TW272942B (enExample) 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
DK41193D0 (da) 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
AU6633694A (en) 1993-04-09 1994-11-08 Board Of Regents Of The University Of Nebraska, The Novel methods and compositions for the treatment of (ras)-activated cancer with heterotypic anti-(raf) antisense oligonucleotides
GB9308802D0 (en) 1993-04-28 1993-06-09 Smithkline Beecham Plc Treatment
DE4322806A1 (de) 1993-07-08 1995-01-12 Janich Gmbh & Co Vorrichtung zur Abdichtung zwischen zwei Anlagenteilen
IL110296A (en) 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US6514745B1 (en) 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
EP0724588B1 (en) 1993-09-17 1999-11-10 Smithkline Beecham Corporation Drug binding protein
US5869043A (en) 1993-09-17 1999-02-09 Smithkline Beecham Corporation Drug binding protein
US6361773B1 (en) 1993-09-17 2002-03-26 Smithkline Beecham Corporation Antibodies produced against cytokine suppressive anti-inflammatory drug binding proteins
US5783664A (en) 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
CA2133815A1 (en) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US5596001A (en) 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
DE69433501T2 (de) 1993-11-08 2004-11-04 Smithkline Beecham Corp. Oxazole zur behandlung von zytokinvermittelten erkrankungen
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
JPH07141053A (ja) 1993-11-17 1995-06-02 Nec Niigata Ltd クロック発生回路
JP4105761B2 (ja) 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン（マクロライド）の半合成類似体免疫調節剤
SG64372A1 (en) 1993-12-17 1999-04-27 Novartis Ag Rapamycin derivatives
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
CH686211A5 (de) 1994-01-27 1996-02-15 Ciba Geigy Ag Motten- und Koferschutzmittel.
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
DE4412334A1 (de) 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US5871918A (en) 1996-06-20 1999-02-16 The University Of North Carolina At Chapel Hill Electrochemical detection of nucleic acid hybridization
AU698953B2 (en) 1994-04-29 1998-11-12 Applied Biosystems, Llc System for real time detection of nucleic acid amplification products
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5744362A (en) 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5656612A (en) 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5447957A (en) 1994-06-02 1995-09-05 Smithkline Beecham Corp. Anti-inflammatory compounds
US5470882A (en) 1994-06-02 1995-11-28 Smithkline Beecham Corp. Anti-inflammatory compounds
WO1995033458A1 (en) 1994-06-02 1995-12-14 Smithkline Beecham Corporation Anti-inflammatory compounds
US5786362A (en) 1994-06-16 1998-07-28 University Of Miami Method of treating Hormone independent cancer
EP0690344A1 (en) 1994-06-29 1996-01-03 Konica Corporation Silver halide color photographic light-sensitive material
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
FR2722319B1 (fr) 1994-07-08 1996-08-14 Thomson Csf Dispositif de visualisation couleurs
US5597719A (en) 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
ATE220661T1 (de) 1994-10-19 2002-08-15 Novartis Erfind Verwalt Gmbh Antivirale ether von aspartat-protease-substrat- isosteren
CA2161376C (en) 1994-10-27 2005-01-11 Toshiaki Minami Reversible multi-color thermal recording medium
JP3591938B2 (ja) 1994-10-27 2004-11-24 キヤノン株式会社 インクジェット用記録媒体及びこれを用いた画像形成方法
MA23707A1 (fr) 1994-10-28 1996-07-01 Novozymes As Procede pour le finissage chimique de polymeres insolubles
US5723290A (en) 1994-11-03 1998-03-03 Trustees Of The University Of Pennsylvania Methods for profiling mRNA expression in neurites
TW313568B (enExample) 1994-12-20 1997-08-21 Hoffmann La Roche
US5780483A (en) 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
JPH11503110A (ja) 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
US5814646A (en) 1995-03-02 1998-09-29 Eli Lilly And Company Inhibitors of amyloid beta-protein production
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
DE19512639A1 (de) 1995-04-05 1996-10-10 Merck Patent Gmbh Benzonitrile und -fluoride
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
AU712193B2 (en) 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
US5994063A (en) 1995-06-23 1999-11-30 Metzker; Michael L. Substituted 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene compounds for homogenous amplification/detection assays
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
MX9604165A (es) 1995-09-18 1997-10-31 Sankyo Co Nuevos derivados de urea que tienen actividad inhibidora de acil-coa: colesterol acil transferasa; su preparacion y su uso terapeutico y profilactico.
US6075040A (en) 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
SE510846C2 (sv) 1995-11-06 1999-06-28 Moelnlycke Health Care Ab Innerförpackning för i en yttre förpackning sterilförpackade bukdukar
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
DE69627709T2 (de) 1995-12-28 2004-02-26 Kureha Kagaku Kogyo K.K. N-(unsubstituierte oder substituierte)-4-substituierte-6-(unsubstituierte oder substituierte)phenoxy-2-pyridincarboxamide oder -thiocarboxamide, verfahren zu deren herstellung sowie herbizide
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6005008A (en) 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6103692A (en) 1996-03-12 2000-08-15 The General Hospital Corporation Inhibiting protein interactions
US6211373B1 (en) 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
DE69701298T2 (de) 1996-04-15 2000-10-05 Takeda Chemical Industries, Ltd. Hydroxypyridin-Derivate, ihre Herstellung und ihre pharmazeutische Verwendung
IL126674A (en) 1996-04-23 2005-08-31 Vertex Pharma Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
JPH09301858A (ja) 1996-05-13 1997-11-25 Senju Pharmaceut Co Ltd グルコン酸クロルヘキシジン安定化水性薬剤
IL126922A0 (en) 1996-05-24 1999-09-22 Neurosearch As Phenyl derivatives containing an acidic group their preparation and their use as chloride channel blockers
US5910417A (en) 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
EP0907362A4 (en) 1996-06-27 1999-12-01 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
HUP9903922A3 (en) 1996-06-27 2001-12-28 Smithkline Beecham Corp Il-8 receptor antagonists
EP0932405A4 (en) 1996-06-27 2001-10-17 Smithkline Beckman Corp IL-8 RECEPTOR ANTAGONISTS
JP2000514049A (ja) 1996-06-27 2000-10-24 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８受容体拮抗薬
CZ59398A3 (cs) 1996-06-29 1998-07-15 Samjin Pharmaceutical Co., Ltd. Piperazinové deriváty a způsob jejich přípravy
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
WO1998017207A1 (en) 1996-10-21 1998-04-30 Synthes Ag Chur Surgical prosthetic device
US5965573A (en) 1996-10-23 1999-10-12 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
WO1998017267A1 (en) 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
ATE454141T1 (de) 1996-11-15 2010-01-15 Cytokine Pharmasciences Inc Guanylhydrazone die nützlich sind zur behandlung von mit t-zellen verbundenen krankheiten
GB9623833D0 (en) 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
WO1998022432A1 (en) 1996-11-18 1998-05-28 Yamanouchi Pharmaceutical Co., Ltd. Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same
FR2755967B1 (fr) 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
HUP0001943A3 (en) 1997-01-23 2002-12-28 Smithkline Beecham Corp Benzimidazole and benzotriazole derivatives, their use, process for their preparation and pharmaceutical compositions containing them
US5929250A (en) 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
ES2224365T3 (es) 1997-02-12 2005-03-01 Smithkline Beecham Corporation Antagonistas de receptores de il-8.
WO1998045268A1 (en) 1997-04-04 1998-10-15 Pfizer Products Inc. Nicotinamide derivatives
US20020111495A1 (en) 1997-04-04 2002-08-15 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
AU6783698A (en) 1997-04-10 1998-10-30 Pharmacia & Upjohn Company Polyaromatic antiviral compositions
WO1998049150A1 (en) 1997-04-25 1998-11-05 Takeda Chemical Industries, Ltd. Triazine derivatives, their production and agrochemical composition
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
RU2249591C2 (ru) 1997-05-22 2005-04-10 Дж.Д. Серл Энд Ко. 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38
CA2288787A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. Pyrazole derivatives as p38 kinase inhibitors
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
EP0986382B1 (en) 1997-05-23 2008-06-25 Bayer Pharmaceuticals Corporation Raf kinase inhibitors
DE1019040T1 (de) 1997-05-23 2001-02-08 Bayer Corp., West Haven Hemmung von p38 kinase aktivität durch arylharnstoff
US6344476B1 (en) * 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US6150395A (en) 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
US5985592A (en) 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
EP1020444A4 (en) 1997-06-27 2001-04-11 Kureha Chemical Ind Co Ltd 6-PHENOXYPICOLINIC ACID, ALKYLIDENEHYDRAZIDE DERIVATIVES, THEIR PRODUCTION PROCESS, AND HERBICIDE
US6525065B1 (en) 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
AUPP003197A0 (en) 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
WO1999020617A1 (en) 1997-10-21 1999-04-29 Active Biotech Ab Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors
CA2303848C (en) 1997-10-31 2008-09-30 Rhone-Poulenc Rorer Limited Substituted anilides
CA2308428A1 (en) 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6018065A (en) 1997-11-10 2000-01-25 Advanced Technology Materials, Inc. Method of fabricating iridium-based materials and structures on substrates, iridium source reagents therefor
IL135176A0 (en) 1997-11-10 2001-05-20 Bristol Myers Squibb Co Benzothiazole derivatives and pharmaceutical compositions containing the same
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
WO1999028305A1 (en) 1997-12-01 1999-06-10 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
US6635421B1 (en) 1997-12-09 2003-10-21 Children's Medical Center Corporation Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
SK282727B6 (sk) 1997-12-19 2002-11-06 Slovakofarma, A. S. 1,3-Disubstituované močoviny - inhibítory ACAT a spôsob ich prípravy
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
DE69836563T2 (de) 1997-12-22 2007-05-16 Bayer Pharmaceuticals Corp., West Haven INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN
NZ505844A (en) 1997-12-22 2003-10-31 Bayer Ag Inhibition of raf kinase using substituted heterocyclic ureas
PL341356A1 (en) 1997-12-22 2001-04-09 Bayer Ag Raf kinase inhibition employing aryl- and heteroaryl-substituted heterocyclic ureas
ATE529109T1 (de) 1997-12-22 2011-11-15 Bayer Healthcare Llc Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
AU1939999A (en) 1997-12-22 1999-07-12 Bayer Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20120046290A1 (en) * 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
HU227711B1 (en) 1997-12-22 2011-12-28 Bayer Healthcare Llc Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas and pharmaceutical compositions containing them
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
WO1999032109A1 (en) 1997-12-23 1999-07-01 Bristol-Myers Squibb Company 7-deoxy-6-nitrogen substituted paclitaxels
AU1689999A (en) 1997-12-25 1999-07-19 Daiichi Pharmaceutical Co., Ltd. Medicinal composition for percutaneous administration
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
WO1999037604A2 (en) 1998-01-21 1999-07-29 Zymogenetics, Inc. Dialkyl ureas as calcitonin mimetics
FR2774824B1 (fr) 1998-02-09 2000-04-28 Moving Magnet Tech Actionneur lineaire ameliore
EP1057033B1 (en) 1998-02-18 2003-04-23 Theryte Limited Treating cancer
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
US6413773B1 (en) 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6667340B1 (en) 1998-06-26 2003-12-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibitors of phosphatidyl myo-inositol cycle
US6352977B1 (en) 1998-07-13 2002-03-05 Aventis Pharma Limited Substituted β-alanines
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CA2337755C (en) 1998-09-18 2008-07-29 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6383734B1 (en) 1998-09-30 2002-05-07 Advanced Research And Technology Institute, Inc. Method to determine inhibition of PAK3 activation of Raf-1
US6130053A (en) 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
CA2347916A1 (en) 1998-11-06 2000-05-18 Basf Aktiengesellschaft Inhibition of the formation of vascular hyperpermeability
AU2156600A (en) 1998-11-25 2000-06-13 Cold Spring Harbor Laboratory Methods and reagents for increasing proliferative capacity and preventing replicative senescence
US6114517A (en) 1998-12-10 2000-09-05 Isis Pharmaceuticals Inc. Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
WO2000035455A1 (en) 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035454A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6147107A (en) 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
CA2356263C (en) 1998-12-25 2009-04-21 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
US6351764B1 (en) 1998-12-31 2002-02-26 Michael Voticky System and method for prioritizing communications messages
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
TWI284642B (en) 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
ATE253051T1 (de) 1999-01-22 2003-11-15 Kirin Brewery Chinolinderivate und chinazolinderivate
AU2804400A (en) 1999-02-12 2000-08-29 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
WO2000050425A1 (en) 1999-02-22 2000-08-31 Boehringer Ingelheim Pharmaceuticals, Inc. Polycyclo heterocyclic derivatives as antiinflammatory agents
IL144897A0 (en) 1999-03-12 2002-06-30 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
ATE309237T1 (de) 1999-03-12 2005-11-15 Boehringer Ingelheim Pharma Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
EP1964561A1 (en) 1999-03-19 2008-09-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
ATE467620T1 (de) 1999-03-26 2010-05-15 Euro Celtique Sa Arylsubstituierte pyrazole, imidazole, oxazole, thiazole und pyrrole, sowie deren verwendung
US6140124A (en) 1999-04-06 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of P38 mitogen activated protein kinase expression
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
WO2000068223A1 (en) 1999-05-05 2000-11-16 Aventis Pharma Limited Ureas and their use as cell adhesion modulators
KR20020000223A (ko) 1999-05-14 2002-01-05 존 비. 랜디스 표피성장인자 수용체 길항제를 사용한 인간 난치성 종양의치료 방법
HN2000000051A (es) 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
TWI234557B (en) 1999-05-26 2005-06-21 Telik Inc Novel naphthalene ureas as glucose uptake enhancers
DE19927835A1 (de) 1999-06-18 2000-12-21 Clariant Gmbh Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten
ATE312823T1 (de) 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
DE60024631T2 (de) 1999-07-26 2006-06-14 Banyu Pharma Co Ltd Biaryl-harnstoff-derivate
EP1200395B1 (en) 1999-07-28 2006-03-29 Kirin Beer Kabushiki Kaisha Urea derivatives as inhibitors of ccr-3 receptor
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US6372933B1 (en) 1999-08-26 2002-04-16 Smithkline Beecham Corporation Process for preparing certain phenyl urea compounds
WO2001054727A1 (en) 1999-10-15 2001-08-02 The Van Kampen Group, Inc. Treatment of dermal tumors, warts, and viral infections using heat-killed p. acnes
US6420378B1 (en) 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001036403A1 (en) 1999-11-16 2001-05-25 Boehringer Ingelheim Pharmaceuticals, Inc. Urea derivatives as anti-inflammatory agents
US8815517B2 (en) * 1999-12-28 2014-08-26 Ribonomics, Inc. Methods for identifying functionally related genes and drug targets
EP1242382B1 (en) 1999-12-29 2007-02-07 Wyeth Tricyclic protein kinase inhibitors
CA2397417A1 (en) * 2000-01-12 2001-07-19 Sarah S. Bacus Method for quantitating a protein by image analysis
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
AU2001236698A1 (en) 2000-02-07 2001-08-14 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US6658473B1 (en) 2000-02-25 2003-12-02 Sun Microsystems, Inc. Method and apparatus for distributing load in a computer environment
CA2401665A1 (en) 2000-03-02 2001-09-07 Ludwig Institute For Cancer Research Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
WO2001066099A2 (en) 2000-03-06 2001-09-13 Astrazeneca Ab Use of quinazoline derivatives as angiogenesis inhibitors
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US6390102B1 (en) 2000-07-14 2002-05-21 General Electric Company Silicone compositions for personal care products and method for making
EP1311277A4 (en) 2000-07-18 2004-08-25 Joslin Diabetes Center Inc METHODS OF FIBROSIS MODULATION
US6565880B2 (en) 2000-07-24 2003-05-20 Boehringer Ingelheim Pharmaceuticals, Inc. Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
WO2002012284A2 (en) 2000-08-04 2002-02-14 Loma Linda University Medical Center Iron regulating protein-2 (irp-2) as a diagnostic for neurodegenerative disease
MXPA03001256A (es) 2000-08-11 2004-12-06 Vertex Pharma Inhibidores de p38.
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
EP1489090B1 (en) 2000-08-17 2006-02-01 The Kitasato Institute Novel pseudoerythormycin derivatives
CZ2003468A3 (cs) 2000-08-31 2004-05-12 Pfizeráproductsáinc Deriváty pyrazolu a jejich použití jako inhibitorů proteinkinázy
WO2002025286A2 (en) 2000-09-20 2002-03-28 The President And Fellows Of Harvard College Methods for the diagnosis of neoplastic disorders using angiogenin
AUPR034000A0 (en) 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
WO2002032872A1 (fr) 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
JP3768800B2 (ja) 2000-10-31 2006-04-19 キヤノン株式会社 画像形成装置
AU2002223500A1 (en) 2000-11-17 2002-05-27 Novo-Nordisk A/S Glucagon antagonists/inverse agonists
EP1345707A1 (en) 2000-11-27 2003-09-24 Eric A. Brill System, method, and program for sorting objects
YU36403A (sh) 2000-11-28 2006-08-17 Pfizer Products Inc. Soli izotiazol-4-karboksamida kao anti-hiperproliferacioni agensi
EP1341771A2 (en) 2000-11-29 2003-09-10 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
EP1488797B1 (en) 2000-12-08 2008-04-23 Kyowa Hakko Kogyo Co., Ltd. Oral preprations having itching-relieving or antipruritic activity
CZ20031751A3 (cs) 2000-12-21 2004-03-17 Glaxo Group Limited Makrolidy
KR100362390B1 (ko) 2000-12-29 2002-11-23 삼성전자 주식회사 화상형성장치의 현상기-토너 카트리지 조립체
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2435829A1 (en) 2001-01-25 2002-08-01 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
FR2820136A1 (fr) 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
WO2002059081A2 (en) 2001-01-26 2002-08-01 Kirin Beer Kabushiki Kaisha Urea derivatives as inhibitors of ccr-3 receptor
US6670364B2 (en) 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
PT2269603E (pt) 2001-02-19 2015-09-09 Novartis Ag Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
US6525091B2 (en) 2001-03-07 2003-02-25 Telik, Inc. Substituted diarylureas as stimulators for Fas-mediated apoptosis
ATE366720T1 (de) 2001-03-07 2007-08-15 Telik Inc Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
UY27225A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
WO2002078766A2 (en) 2001-04-02 2002-10-10 Genentech, Inc. Combination therapy
CA2490819A1 (en) 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2002083628A1 (en) 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused compounds
US20030207914A1 (en) 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2002088090A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
JP2004530690A (ja) 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症性薬剤として有用なジアリールウレア誘導体
EP1402054A4 (en) * 2001-05-25 2005-08-17 Immunex Corp ATTRACTIN / MAHOGANY POLYPEPTIDES, POLYNUCLEOTIDES, ANTIBODIES AND METHODS OF USE
WO2003004523A1 (en) 2001-07-02 2003-01-16 Bayer Aktiengesellschaft Regulation of human citron rho/rac-interacting kinase
US6916814B2 (en) 2001-07-11 2005-07-12 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
ES2400070T3 (es) 2001-12-03 2013-04-05 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
CA2466762A1 (en) 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
AU2002353228B2 (en) 2001-12-21 2008-09-11 The Welcome Trust Genes
US20040096855A1 (en) 2001-12-24 2004-05-20 Michael Stratton Genes
AU2002356323A1 (en) 2001-12-24 2003-07-30 Catalyst Biomedica Limited Cancer-specific mutants of b-raf genes and uses thereof
US20030207872A1 (en) 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
AU2003207961A1 (en) 2002-01-16 2003-07-30 Ramot At Tel Aviv University Ltd. Compositions and their use for enhancing and inhibiting fertilization
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20040023961A1 (en) 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
JP4628678B2 (ja) 2002-03-29 2011-02-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 置換ベンズアゾールおよびＲａｆキナーゼ阻害剤としてのそれらの使用
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
DE10221524A1 (de) 2002-05-14 2003-12-04 Kmb Produktions Ag Felben Verfahren und Vorrichtung zum Herstellen von Verzehrgütern
US20040018528A1 (en) 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
EP1545523A1 (en) 2002-07-03 2005-06-29 Astex Technology Limited 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS
ES2311120T3 (es) 2002-08-27 2009-02-01 Merck Patent Gmbh Derivados de glicinamida como inhibidores de quinasa-raf.
PL374758A1 (en) 2002-10-24 2005-10-31 Merck Patent Gmbh Methylene urea derivatives
CA2504933C (en) 2002-11-06 2012-10-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
BR0316279A (pt) 2002-11-15 2005-10-11 Novartis Ag Compostos orgânicos
SE0203654D0 (sv) 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
US20030232400A1 (en) 2002-12-20 2003-12-18 Susan Radka Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
JP4594925B2 (ja) 2003-02-28 2010-12-08 ニッポネックス インコーポレイテッド 増殖亢進性、血管新生性及び炎症性疾患の治療に有用な２−オキソ−１，３，５−パーヒドロトリアザピン誘導体
EP1608639A2 (en) * 2003-02-28 2005-12-28 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
JP4927533B2 (ja) 2003-02-28 2012-05-09 ニッポネックス インコーポレイテッド 癌その他の疾患の治療に有用な置換ピリジン誘導体
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
AU2004224239A1 (en) 2003-03-24 2004-10-07 Merck Patent Gmbh Oxamide derivatives useful as RAF-kinase inhibitors
WO2004084889A1 (en) 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
US6896863B2 (en) 2003-04-01 2005-05-24 E. I. Du Pont De Nemours And Company Sodium cyanide process
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
JP2006526606A (ja) 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 治療薬としてのシクロアルキル及びヘテロシクロアルキル置換されるベンゾチオフェン
US20040259926A1 (en) 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US20070213374A1 (en) 2003-07-07 2007-09-13 Merck Patent Gmbh Malonamide Derivatives
WO2005005434A1 (en) 2003-07-08 2005-01-20 Novartis Ag Use of rapamycin and rapamycin derivatives for the treatment of bone loss
ATE538787T1 (de) 2003-07-11 2012-01-15 Merck Patent Gmbh Benzimidazol-derivative als raf-kinase-hemmer
CA2531856C (en) 2003-07-11 2013-07-30 Merck Patent Gesellschaft Mit Beschraenkter Haftung Benzimidazole carboxamides as raf kinase inhibitors
EP1648900A4 (en) 2003-07-11 2010-02-10 Ariad Pharma Inc PHOSPHORUS MACROCYCLES
WO2005009367A2 (en) 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors
HRP20060073B1 (hr) 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
TW200523262A (en) 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity
DE10334663A1 (de) 2003-07-30 2005-03-10 Merck Patent Gmbh Harnstoffderivate
EP1668360A4 (en) 2003-08-15 2007-08-08 Univ Pittsburgh MULTI FACTOR CANCER DETECTION TEST
MXPA06003163A (es) 2003-09-23 2006-06-05 Novartis Ag Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico.
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
JP2007509846A (ja) 2003-10-15 2007-04-19 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロ−ナフタレンおよび尿素誘導体
CA2542653A1 (en) 2003-10-16 2005-04-28 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
CA2542329A1 (en) 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
DE10349587A1 (de) 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
US20050165031A1 (en) 2003-11-13 2005-07-28 Ambit Biosciences Corporation Urea derivatives as ABL modulators
DE10352979A1 (de) 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
DE10354060A1 (de) 2003-11-19 2005-06-02 Merck Patent Gmbh Pyrrolderivate
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
US8044057B2 (en) 2003-12-09 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for suppressing an immune response or treating a proliferative disorder
WO2005058832A1 (en) 2003-12-10 2005-06-30 Merck Patent Gmbh Diacylhydrazine derivatives
CA2548394A1 (en) 2003-12-12 2005-06-30 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
KR20060132882A (ko) 2004-01-30 2006-12-22 메르크 파텐트 게엠베하 비스아릴우레아 유도체
US20050267060A1 (en) 2004-03-19 2005-12-01 The Penn State Research Foundation Combinatorial methods and compositions for treatment of melanoma
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
WO2006026501A1 (en) 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation New pharmaceutical compositions for the treatment of cancer
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
ATE517901T1 (de) 2004-09-06 2011-08-15 Bayer Schering Pharma Ag Pyrazolopyrimidine als hemmer der proteinkinase b (akt)
PL1797038T3 (pl) 2004-09-29 2012-11-30 Bayer Healthcare Llc Termodynamicznie trwała postać tosylanu bay 43-9006
BRPI0515944B1 (pt) 2004-09-29 2021-11-09 Bayer Healthcare Llc Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida
US7625931B2 (en) 2005-01-14 2009-12-01 Cgi Pharmaceuticals, Inc. Certain substituted diphenyl ureas, as modulators of kinase activity
CN104688697A (zh) 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
DE102005015253A1 (de) 2005-04-04 2006-10-05 Merck Patent Gmbh Pyrazolderivate
MX2007014726A (es) 2005-05-27 2008-02-14 Bayer Healthcare Ag Tratamiento combinado que comprende un compuesto diarilurea y una pi3, akt cinasa o inhibidores mtor (rapamicina) para tratamiento de cancer.
JP2008545670A (ja) 2005-05-27 2008-12-18 バイエル・ヘルスケア・アクチェンゲゼルシャフト 疾患を処置するためのジアリールウレア類を含む組合せ治療
EP1937837A2 (en) 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
ATE493652T1 (de) 2005-08-11 2011-01-15 Siemens Healthcare Diagnostics Quantitative assays für pdgfr-beta- in körperflüssigkeiten
EP1928872B1 (en) 2005-09-21 2012-03-14 4Sc Ag Novel sulphonylpyrroles as inhibitors of hdac
CN101287706A (zh) 2005-09-21 2008-10-15 尼科梅德有限责任公司 作为组蛋白脱乙酰基酶抑制剂的磺酰基吡咯盐酸盐
WO2007047955A2 (en) 2005-10-21 2007-04-26 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EP1968589A2 (en) 2005-10-31 2008-09-17 Bayer Pharmaceuticals Corporation Combinations comprising sorafenib and interferon for the treatment of cancer
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
EP1954272A2 (en) 2005-10-31 2008-08-13 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
EP1946116A4 (en) 2005-11-02 2010-01-06 Bayer Healthcare Llc METHOD FOR PREDICTING AND FORECASTING CANCER AND MONITORING CANCER THERAPY
BRPI0618564A2 (pt) 2005-11-02 2011-09-06 Bayer Healthcare Llc métodos para predição e prognóstico de cáncer e para monitoração de terapia contra cáncer
CA2628849A1 (en) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating pulmonary hypertension
JP5075832B2 (ja) 2005-11-10 2012-11-21 バイエル・ファルマ・アクチェンゲゼルシャフト 肺高血圧を処置するためのジアリールウレア
AU2006315592A1 (en) 2005-11-14 2007-05-24 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007059155A1 (en) 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Treatment of cancers having resistance to chemotherapeutic agents
CA2629863A1 (en) * 2005-11-14 2007-05-24 Scott Wilhelm Use of sorafenib for the treatment of cancers with acquired resistance to kit inhibitors
MX2008006979A (es) 2005-12-01 2009-01-14 Bayer Healthcare Llc Compuestos de urea utiles en el tratamiento contra el cancer.
US20090227637A1 (en) 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
CA2633400A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl urea for treating virus infections
EP1962829A1 (en) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryl ureas for treating virus infections
EP1973897B1 (en) * 2005-12-21 2014-05-21 Bayer Intellectual Property GmbH Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
WO2007087575A2 (en) 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
KR20080103977A (ko) 2006-02-22 2008-11-28 4에스체 악티엔게젤샤프트 Ｅｇ５ 키네신 조절자로서 인돌로피리딘
US8530493B2 (en) 2006-02-22 2013-09-10 4Sc Ag Indolopyridines as Eg5 kinesin modulators
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
CA2648106A1 (en) 2006-03-31 2007-11-01 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
JP2009538317A (ja) 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2667720A1 (en) 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2008055629A1 (en) * 2006-11-09 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
WO2008058644A1 (en) * 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
EP2111401B1 (en) 2006-12-20 2011-02-16 Bayer HealthCare, LLC 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino]-3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
CA2672951A1 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc Hydroxy methyl phenyl pyrazolyl urea compound useful in the treatment of cancer
JP2010516692A (ja) * 2007-01-19 2010-05-20 バイエル・ヘルスケア・エルエルシー 化学療法剤に対し抵抗性を有する癌の処置
CA2675980C (en) * 2007-01-19 2016-06-21 Bayer Healthcare Llc Use of dast for treatment of cancers with acquired resistance to kit inhibitors
NZ583790A (en) 2007-09-10 2012-04-27 Cipla Ltd Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process
WO2009054004A2 (en) 2007-10-22 2009-04-30 Natco Pharma Limited Process for the preparation of sorafenib
FR2929509B1 (fr) * 2008-04-02 2011-01-21 Lvmh Rech L'utilisation de glycosides d'alkyle ou de melanges de glycosides d'alkyle en tant qu'agents destines a inhiber la croissance microbienne, et compositions contenant lesdits glycosides d'alkyle.
EP2296641A1 (en) * 2008-06-25 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
CA2741087A1 (en) * 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
US8722715B2 (en) 2008-11-07 2014-05-13 NovaBay Pharmaceuticals Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
JP5821626B2 (ja) 2011-12-27 2015-11-24 富士ゼロックス株式会社 画像形成装置及びプログラム

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041698A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
WO2002085859A1 (en) * 2001-04-20 2002-10-31 Bayer Corporation HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
WO2002085857A2 (en) * 2001-04-20 2002-10-31 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515400A (ja) * 2003-11-28 2007-06-14 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体
JP2009519265A (ja) * 2005-12-15 2009-05-14 バイエル・ヘルスケア・アクチェンゲゼルシャフト ウイルス感染を処置するためのジアリールウレア
JP2010516693A (ja) * 2007-01-19 2010-05-20 バイエル・ヘルスケア・エルエルシー Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置
JP2013238609A (ja) * 2007-05-18 2013-11-28 Inst Curie 膀胱癌における治療標的としてのｐ３８α
JP2016104785A (ja) * 2009-09-03 2016-06-09 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ チロシンキナーゼ調節剤としての化合物
JP2019528279A (ja) * 2016-08-17 2019-10-10 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害物質化合物、組成物、及びがんの治療方法
JP2020517600A (ja) * 2017-04-20 2020-06-18 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｋ−Ｒａｓモジュレーター

Also Published As

Publication number Publication date
CA2526636A1 (en) 2005-01-06
US8796250B2 (en) 2014-08-05
EP1636585B1 (en) 2008-01-16
MXPA05012486A (es) 2006-07-03
CA2526617A1 (en) 2004-12-29
ATE384264T1 (de) 2008-02-15
PT1626714E (pt) 2007-08-24
DE602004011340T2 (de) 2008-11-06
EP1636585A2 (en) 2006-03-22
US20050059703A1 (en) 2005-03-17
DE602004007382D1 (de) 2007-08-16
PL1636585T3 (pl) 2008-10-31
ES2288694T3 (es) 2008-01-16
EP1626714B1 (en) 2007-07-04
DE602004011340D1 (de) 2008-03-06
WO2004113274A3 (en) 2005-03-03
CA2526617C (en) 2015-04-28
WO2004113274A2 (en) 2004-12-29
EP1636585B2 (en) 2012-06-13
PL1626714T3 (pl) 2007-12-31
WO2005000284A3 (en) 2005-03-10
EP1626714A2 (en) 2006-02-22
US20070020704A1 (en) 2007-01-25
CA2526636E (en) 2005-01-06
JP4860474B2 (ja) 2012-01-25
WO2005000284A2 (en) 2005-01-06
DE602004007382T2 (de) 2008-04-17
CA2526636C (en) 2012-10-02
ES2305808T3 (es) 2008-11-01
JP2006528986A (ja) 2006-12-28
DK1626714T3 (da) 2007-10-15
PT1636585E (pt) 2008-03-27
ATE366108T1 (de) 2007-07-15
DK1636585T3 (da) 2008-05-26

Similar Documents

Publication Publication Date Title
JP2007511203A (ja) キナーゼ阻害活性を有するジアリール尿素
JP5505906B2 (ja) 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
EP2111401B1 (en) 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino]-3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
JP4658037B2 (ja) 癌および他の障害の処置に有用な新規シアノピリジン誘導体
US20110195110A1 (en) Urea compounds useful in the treatment of cancer
EP2134677B1 (en) 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-chlorophenoxy}-n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
MXPA05012491A (en) Diaryl ureas with kinase inhibiting activity
HK1093978B (en) Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
HK1141518A (en) 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
HK1179259B (en) Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
HK1089155B (en) Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100615

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100716

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100811

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111220

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120106

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120713

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120719